QuidelOrtho Corporation (QDEL)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of QuidelOrtho Corporation (“QuidelOrtho” or “the Company”) (NASDAQ: QDEL). Investors who purchased QuidelOrtho securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether QuidelOrtho has violated federal securities laws.

Investigation Details:

On February 13, 2024, QuidelOrtho issued a press release announcing its fourth quarter and full-year 2023 financial results. Among other items, QuidelOrtho reported non-GAAP earnings per share of $1.17, missing consensus estimates by $0.89, and revenue of $742.6 million, missing consensus estimates by $44.86 million. QuidelOrtho’s disappointing financial results prompted downgrades by analysts at J.P. Morgan and William Blair. On this news, QuidelOrtho’s stock price fell $21.50 per share, or 32.2%, to close at $45.27 per share on February 14, 2024.

What’s Next?

If you are aware of any facts relating to this investigation or purchased QuidelOrtho securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

332-239-2660 | [email protected]